Healthcare Industry News: endoluminal intragastric surgery
News Release - April 13, 2007
EndoGastric Solutions Hires Seasoned Chief Financial Officer and Director of US Sales Experienced in Launching Leading-Edge Medical TechnologyREDMOND, Wash., April 13 (HSMN NewsFeed) -- EndoGastric Solutions, the world leader in endoluminal intragastric surgery, is pleased to announce the appointment of Guy Seaton to the position of Chief Financial Officer and Larry Fulton as Senior Director of US Sales.
"We are extremely pleased to have Guy and Larry on our team. They are joining us at the same time we are launching our first product in the United States," said Thierry Thaure, President and CEO of EndoGastric Solutions. "Their experience bringing companies and products from concept to full commercialization will help us continue to build a strong company from both a product standpoint as well as strengthen our position as the leader in incisionless surgery."
With more than 25 years of experience in corporate finance, Mr. Seaton has a strong track record of bringing companies including InControl Inc., SonoSite Inc. and Corus Pharma Inc. from venture-stage companies to the next level in the development process.
"EndoGastric Solutions' technology has the potential to make a dramatic impact in the marketplace," said Mr. Seaton. "EsophyX(TM) has been well- received in Europe and, with StomaphyX(TM) now cleared in the US, this is an incredible opportunity to continue the company's success by iterating the current products while continuing to develop a full spectrum of products to treat a number of diseases."
Leading the US sales team, Mr. Fulton brings over 15 years of experience in minimally invasive surgery and, most recently, spent seven years in Executive Sales management roles at Inamed Health/BioEnterics where he was a key player in bringing the Lap-Band® from clinical trials to mass market.
"From my experience, EGS is on track to continue its success because our products are revolutionizing the way physicians treat GERD and other diseases," said Mr. Fulton. "The response that we have received with the US launch of StomaphyX has been incredible. Many of the people I have been talking with see a tremendous opportunity for this product and the technology -- something at or beyond the scale of what laparoscopic surgery was able to accomplish when it was adopted."
About EndoGastric Solutions, Inc.
EndoGastric Solutions(TM) is a pioneer in endoluminal procedures for the treatment of gastrointestinal diseases, including GERD and obesity. EndoGastric Solutions' mission is to utilize the most current wisdom in gastroenterology and surgery to develop new transoral procedures and products to address the largest unmet needs in gastrointestinal diseases. EndoGastric Solutions technologies involve modifying current open surgical and/or laparoscopic approaches by using transoral access instead of abdominal incisions. The company designs and manufactures single-use instruments that will enable these incisionless solutions, and focuses on clinically based products for use by gastroenterologists and surgeons.
StomaphyX is available in the United States. EsophyX is not available for sale or use in the United States. Both devices are CE marked and available in the European Union.
For more information about EndoGastric Solutions, Inc., EsophyX and StomaphyX please visit:
In the US: http://www.endogastricsolutions.com
In the EU: http://www.egseurope.eu
Other locations throughout the globe: http://www.egsglobal.net
Source: EndoGastric Solutions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.